Keros Therapeutics (NASDAQ: KROS) director receives RSUs and options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Keros Therapeutics director Jean Jacques Bienaime reported equity awards rather than open-market trades. He received 7,142 shares of Common Stock as a restricted stock unit award, bringing his direct Common Stock holdings to 16,592 shares. The filing also shows a grant of options for 7,433 shares of Common Stock at an exercise price of $10.50 per share. The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, while the options vest in equal quarterly installments over 12 months following June 3, 2026 and in any case are fully vested by the 2027 annual meeting, in each case subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BIENAIME JEAN JACQUES

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,433	$0.00	--
Grant/Award	Common Stock	7,142	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 7,433 shares (Direct, null); Common Stock — 16,592 shares (Direct, null)

Footnotes (1)

Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date. The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Key Figures

RSU award: 7,142 shares Options granted: 7,433 shares Option exercise price: $10.50/share +2 more

5 metrics

RSU award 7,142 shares Restricted stock units granted June 3, 2026

Options granted 7,433 shares Stock options granted June 3, 2026

Option exercise price $10.50/share Exercise price for 7,433-share option grant

Shares held after RSU grant 16,592 shares Common Stock directly held after award

RSU vesting date June 3, 2027 RSUs vest by earlier of June 3, 2027 or 2027 annual meeting

Key Terms

restricted stock unit ("RSU"), Stock Option (right to buy), exercise price, annual meeting of stockholders

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award."

Stock Option (right to buy) financial

"Security title is listed as Stock Option (right to buy)."

exercise price financial

"Conversion or exercise price reported as 10.5000 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual meeting of stockholders financial

"Fully vested on the date of Issuer's 2027 annual meeting of stockholders."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/05/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIENAIME JEAN JACQUES

(Last)

(First)

(Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/03/2026		A		7,142⁽¹⁾	A	$0	16,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$10.5	06/03/2026		A		7,433		⁽²⁾	06/02/2036	Common Stock	7,433	$0	7,433	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

2. The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Esther Cho, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Keros Therapeutics (KROS) disclose in this Form 4?

The Form 4 shows director Jean Jacques Bienaime received 7,142 restricted stock units and options for 7,433 shares at $10.50 per share, reflecting compensation-related equity awards instead of open-market buying or selling.

How many Keros Therapeutics (KROS) shares does the director hold after these awards?

Following the RSU grant, Jean Jacques Bienaime directly holds 16,592 shares of Keros Therapeutics Common Stock. This total reflects his updated equity position after receiving 7,142 RSUs as part of the reported compensation package.

What are the terms of the RSU award reported for Keros Therapeutics (KROS)?

The 7,142 RSUs fully vest on the earlier of June 3, 2027 or the Keros Therapeutics 2027 annual meeting of stockholders, provided Jean Jacques Bienaime continues to provide service to the company through the applicable vesting date.

What are the vesting terms of the stock options granted by Keros Therapeutics (KROS)?

The options for 7,433 shares at a $10.50 exercise price vest in equal quarterly installments over the 12 months following June 3, 2026, and in any case are fully vested by the 2027 annual meeting, subject to continued service.

Do the Keros Therapeutics (KROS) Form 4 transactions involve open-market buying or selling?

No, the reported transactions are compensation-related awards. The Form 4 classifies both the RSU grant and the stock option grant as acquisitions under code A, with no open-market purchases or sales indicated in the summary data.